China Biologic Products Holdings Inc (NASDAQ:CBPO) Sees Large Drop in Short Interest

China Biologic Products Holdings Inc (NASDAQ:CBPO) was the target of a significant decrease in short interest in January. As of January 31st, there was short interest totalling 461,000 shares, a decrease of 11.6% from the January 15th total of 521,700 shares. Currently, 2.7% of the company’s stock are short sold. Based on an average daily volume of 79,600 shares, the days-to-cover ratio is presently 5.8 days.

CBPO has been the subject of a number of research reports. ValuEngine downgraded China Biologic Products from a “hold” rating to a “sell” rating in a report on Tuesday, February 4th. Zacks Investment Research downgraded China Biologic Products from a “buy” rating to a “hold” rating in a report on Thursday, October 24th. Finally, BidaskClub downgraded China Biologic Products from a “sell” rating to a “strong sell” rating in a report on Friday, January 10th. Three analysts have rated the stock with a sell rating and two have assigned a hold rating to the company’s stock. The company has a consensus rating of “Sell” and an average target price of $92.67.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Bank of America Corp DE raised its holdings in China Biologic Products by 5.7% in the fourth quarter. Bank of America Corp DE now owns 889,586 shares of the biopharmaceutical company’s stock worth $103,530,000 after purchasing an additional 48,291 shares in the last quarter. Oxford Asset Management LLP grew its stake in shares of China Biologic Products by 194.7% in the fourth quarter. Oxford Asset Management LLP now owns 211,646 shares of the biopharmaceutical company’s stock worth $24,631,000 after acquiring an additional 139,831 shares during the last quarter. Nikko Asset Management Americas Inc. grew its stake in shares of China Biologic Products by 18.1% in the third quarter. Nikko Asset Management Americas Inc. now owns 129,445 shares of the biopharmaceutical company’s stock worth $14,818,000 after acquiring an additional 19,846 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of China Biologic Products by 154.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 119,316 shares of the biopharmaceutical company’s stock worth $13,886,000 after acquiring an additional 72,376 shares during the last quarter. Finally, Myriad Asset Management Ltd. grew its stake in shares of China Biologic Products by 105.2% in the fourth quarter. Myriad Asset Management Ltd. now owns 67,019 shares of the biopharmaceutical company’s stock worth $7,799,000 after acquiring an additional 34,362 shares during the last quarter. Institutional investors and hedge funds own 38.68% of the company’s stock.

CBPO traded up $0.29 during trading on Friday, reaching $116.78. The stock had a trading volume of 100,009 shares, compared to its average volume of 99,268. The stock’s 50 day moving average is $116.35 and its two-hundred day moving average is $111.37. The company has a market capitalization of $4.60 billion, a price-to-earnings ratio of 28.62 and a beta of 1.16. China Biologic Products has a one year low of $79.06 and a one year high of $119.44.

China Biologic Products (NASDAQ:CBPO) last posted its quarterly earnings data on Wednesday, November 13th. The biopharmaceutical company reported $1.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.52. The business had revenue of $136.10 million during the quarter. China Biologic Products had a return on equity of 9.79% and a net margin of 31.22%. China Biologic Products’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.96 EPS.

China Biologic Products Company Profile

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

Featured Article: Pattern Day Trader – What is the PDT Rule?

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.